University of Leeds Featured PhD Programmes
Imperial College London Featured PhD Programmes
University of Southampton Featured PhD Programmes
Norwich Research Park Featured PhD Programmes
University of Reading Featured PhD Programmes
"clinical" AND "trial"×
10 miles

Cancer / Oncology (clinical trial) PhD Projects, Programs & Scholarships

We have 16 Cancer / Oncology (clinical trial) PhD Projects, Programs & Scholarships

  • "clinical" AND "trial" ×
  • Cancer / Oncology×
  • clear all
Order by 
Showing 1 to 10 of 16
  Patient experience of the Mesothelioma Stratified Therapy Trial (MiST): a qualitative study
  Prof A Tod, Dr B Taylor
Applications accepted all year round

Funding Type

PhD Type

This PhD provides a unique opportunity for a student to conduct a qualitative patient experience health services research study within a complex stratified clinical trial for people with malignant mesothelioma (MM), the Mesothelioma Stratified Therapy Trial (MiST).
  Development and Implementation of Efficient Adaptive Designs in Early Phase Oncology Trials for Novel Agents
  Prof C Yap, Prof J Bliss
Application Deadline: 17 November 2019

Funding Type

PhD Type

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes. We are committed to attracting and developing the best minds in the world to join us in our mission—to make the discoveries that defeat cancer.
  (MCRC Clinical) Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer
  Prof C Faivre-Finn, Dr G Price, Prof C Dive
Application Deadline: 1 December 2019

Funding Type

PhD Type

Project summary. Approximately a third of Non-Small Cell Lung Cancer cases are locally-advanced (LA-NSCLC) at presentation (~13,000 pts a year in the UK) with the majority being unsuitable for curative surgery.
  Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma
  Dr C Jones, Dr O Rossanese
Application Deadline: 17 November 2019

Funding Type

PhD Type

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes. We are committed to attracting and developing the best minds in the world to join us in our mission—to make the discoveries that defeat cancer.
  (MCRC Non-Clinical) Assessing the impact of oxygen tension on the generation of cancer immunity
  Prof J O'Connor, Dr J Honeychurch, Prof K Williams
Application Deadline: 1 December 2019

Funding Type

PhD Type

Project summary. The importance of T-cell immunity to cancer outcome is becoming increasingly well-recognised.
  Integrative computational analysis of molecular and clinical data to dissect heterogeneity of therapy response in sarcomas
  Dr P Huang, Dr M Cheang, Dr A Sadanandam
Application Deadline: 17 November 2019

Funding Type

PhD Type

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes. We are committed to attracting and developing the best minds in the world to join us in our mission—to make the discoveries that defeat cancer.
  MRC DiMeN Doctoral Training Partnership: Investigating the mechanisms leading to CHK1 inhibitor resistance in cancer therapy
  Prof N Perkins, Prof S Rocha, Dr J Hunter
Application Deadline: 6 January 2020

Funding Type

PhD Type

DNA replication stress results from stalled DNA replication forks and is a feature of cancer cells, where it can lead to the genomic instability driving tumorigenesis.
  Identifying novel treatment options for ovarian carcinosarcoma
  Dr H Barker
Application Deadline: 31 January 2020

Funding Type

PhD Type

Location. The Walter and Eliza Hall Institute of Medical Research, University of Melbourne. Supervisors. Prof C. Scott, Dr H. Barker.
  TRANS-CASPS: Translational studies in Cedrianib in Alveolar Soft Part Sarcoma (CASPS) trial.
  Dr C Jones, Dr P Huang
Application Deadline: 17 November 2019

Funding Type

PhD Type

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes. We are committed to attracting and developing the best minds in the world to join us in our mission—to make the discoveries that defeat cancer.
  Tyrosine kinase inhibitors conjugated tumour targeting dyes for the treatment of glioblastoma.
  Dr J Jose, Dr P Choi
Applications accepted all year round

Funding Type

PhD Type

Glioblastoma (GBM) remains a lethal and difficult to treat cancer with a dismal outcome. Although we have a better understanding of the disease progression, a concurrent increase in therapeutic intervention is lagging.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.